In the past (not quite distant) pharmaceutical companies had to carry out a full cycle of works for market presence: development, regulation, production, marketing. For today, companies refused from some types of activities by transferring them to outsourcing: regulatory work, marketing and even production: from phase of packaging to the full technological cycle. This trend appeared due to the necessity to optimize company’s financial resources and integration into the local economy of countries. Released resources are used to develop new drugs. This applies to transnational R&D companies.
However, customers of pharmaceutical contract manufacturing can be companies that have never been producers, for example: pharmaceutical marketing companies, intellectual property owners, «pure» developers who want to plunge into the world of marketing and sales.
A separate type of customer is a pharmaceutical company, which is limited to the certain forms of drugs production, but wants to develop its own portfolio (product) in this direction in a single country, basing on market research of the local market.
Pharmaceutical contract manufacturers are companies with 100% or a partial immersion in this activity. Companies, that partly consume with contract manufacturing are guided by the findings of their own marketing services.
The market for pharmaceutical contract manufacturing also covers intellectual property, legal and regulatory issues.
Full cycle pharmaceutical contract manufacturing is the most complicated process in the field of contract manufacturing of drugs and requires the presence of specialized agent between the customer and the manufacturer.
Contract manufacturing does not equal localization, but company executives understand the benefits of the «local» product, especially in countries with a well developed pharmaceutical industry that can at any time cause a regulatory blow, especially for generic companies, within the framework of domestic producer support and health protection in general.
Author: PavlenkoSergii, Director for the Development of the Association of Organizations of Pharmaceutical Contract Manufacturing
Свежие комментарии